Skip to main content

Advertisement

Log in

FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The value of FDG PET-derived parameters in predicting overall survival (OS), local relapse-free survival (LRFS) and distant relapse-free survival (DRFS) in treated patients with malignant pleural mesothelioma (MPM) was evaluated.

Methods

This retrospective evaluation included 55 MPM patients treated between March 2006 and February 2015 with FDG PET/CT-guided salvage helical tomotherapy (HTT) after previous surgery plus chemotherapy. Univariate Cox regression analysis was performed to assess the impact of the following FDG PET-derived parameters: biological target volume (BTV), mean and maximum standardized uptake values (SUVmean/max), metabolic tumour volume (MTV) and total lesion glycolysis (TLG), measured using different uptake thresholds (40%, 50% and 60%). Logistic regression was then performed to identify the best FDG PET-derived parameters for selecting patients with poorer survival.

Results

The median OS was 9.1 months (range 0.0 – 69.6 months) after the end of HTT; 54/55 patients were dead at the last follow-up. BTV and TLG40, TLG50 and TLG60 were the most significant predictors of OS (p < 0.005). The median OS was 4.8 months in patients with MTV60 >5 cm3 and TLG40 >334.4, compared with 13.8 months and 16.1 months in patients with smaller values, respectively. The median LRFS and DRFS were 6.2 months (range 1.2 – 39.4 months) and 6.5 months (0.0 – 66.4 months), respectively. TLG40, TLG50 and TLG60 were significantly correlated with LRFS (p < 0.015). Median DRFS was 6.4 months in patients with MTV40 >39.6 cm3 and 6.2 months in patients with TLG40 >334.4, compared with 17 months and 18.8 months in patients with smaller values. BTV, TLG40 and MTV40 were also found to be good predictors in patients with poor OS/LRFS/DRFS (median survival times less than the median values).

Conclusion

FDG PET-derived parameters effectively discriminated patients with a poor prognosis and may be helpful in the selection of MPM patients for salvage HTT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716–24. https://doi.org/10.2471/Blt.11.086678.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Peto J, Decarli A, La Vecchia C, Levis F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–72. https://doi.org/10.1038/sj.bjc.6690105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44. https://doi.org/10.1200/Jco.2003.11.136.

    Article  CAS  PubMed  Google Scholar 

  4. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–9. https://doi.org/10.1200/Jco.20005.14.589.

    Article  PubMed  Google Scholar 

  5. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v31–9. https://doi.org/10.1093/annonc/mdv199.

    Article  PubMed  Google Scholar 

  6. Bovolato P, Casadio C, Bille A, Ardissone F, Santambrogio L, Ratto GB, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? J Thorac Oncol. 2014;9:390–6. https://doi.org/10.1097/Jto.0000000000000064.

    Article  PubMed  Google Scholar 

  7. Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240–5. https://doi.org/10.1016/j.lungcan.2013.11.026.

    Article  PubMed  Google Scholar 

  8. Rosenzweig KE, Gupta V, Mychalczak B, Krug LM, Flores R, Rusch VW. Hemithoracic radiation therapy and brachytherapy after pleurectomy/decortication for malignant pleural mesothelioma: results from a 30-year experience. J Clin Oncol. 2005;23(16_suppl):7180. https://doi.org/10.1200/jco.2005.23.16_suppl.7180.

    Article  Google Scholar 

  9. Haas AR, Sterman DH. Malignant pleural mesothelioma update on treatment options with a focus on novel therapies. Clin Chest Med. 2013;34:99–111. https://doi.org/10.1016/j.ccm.2012.12.005.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503–10. https://doi.org/10.1016/j.ctrv.2015.03.011.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Marcq E, Pauwels P, van Meerbeeck JP, Smits ELJ. Targeting immune checkpoints: new opportunity for mesothelioma treatment? Cancer Treat Rev. 2015;41:914–24. https://doi.org/10.1016/j.ctrv.2015.09.006.

    Article  CAS  PubMed  Google Scholar 

  12. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H. Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol. 2007;64:356–66. https://doi.org/10.1016/j.ejrad.2007.08.010.

    Article  PubMed  Google Scholar 

  13. Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, et al. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. Eur J Radiol. 2017;86:92–8. https://doi.org/10.1016/j.ejrad.2016.11.009.

    Article  PubMed  Google Scholar 

  14. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer. 2005;49:S27–32. https://doi.org/10.1016/j.lungcan.2005.03.007.

    Article  PubMed  Google Scholar 

  15. Lammering G, De Ruysscher D, van Baardwijk A, Baumert BG, Borger J, Lutgens L, et al. The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol. 2010;186:471–81. https://doi.org/10.1007/s00066-010-2150-1.

    Article  PubMed  Google Scholar 

  16. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713–22. https://doi.org/10.1378/chest.114.3.713.

    Article  CAS  PubMed  Google Scholar 

  17. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, Di Carli MF, Mauceri C, Treves ST. Assessment of malignant pleural mesothelioma with F-18-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med. 2002;43:1144–9.

    PubMed  Google Scholar 

  18. Ng DCE, Hain SF, O’Doherty MJ, Dussek J. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 2000;41:1443–4.

    CAS  PubMed  Google Scholar 

  19. Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, et al. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000;120:128–33. https://doi.org/10.1067/mtc.2000.106529.

    Article  CAS  PubMed  Google Scholar 

  20. Gregianin M, Dei Rossi F, Cracco E, Zaccaria A, Canton A, Pagan V. PET/CT in the preoperative evaluation of patients with malignant pleural mesothelioma (MPM). Eur J Nucl Med Mol Imaging. 2007;34:S142.

  21. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial F-18-FDG PET scans. J Nucl Med. 2007;48:1449–58. https://doi.org/10.2967/jnumed.107.042333.

    Article  PubMed  Google Scholar 

  22. Fodor A, Fiorino C, Dell’Oca I, Broggi S, Pasetti M, Cattaneo GM, et al. PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. Strahlenther Onkol. 2011;187:736–43. https://doi.org/10.1007/s00066-011-2234-6.

    Article  PubMed  Google Scholar 

  23. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6. https://doi.org/10.1016/0360-3016(95)00060-C.

    Article  CAS  PubMed  Google Scholar 

  24. Gupta V, Mychalczak B, Krug L, Flores R, Bains M, Rusch VW, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045–52. https://doi.org/10.1016/j.ijrobp.2005.03.041.

    Article  PubMed  Google Scholar 

  25. Maggio A, Cutaia C, Di Dia A, Bresciani S, Miranti A, Poli M, et al. Tomotherapy PET-guided dose escalation. Strahlenther Onkol. 2016;192:102–8. https://doi.org/10.1007/s00066-015-0901-8.

    Article  PubMed  Google Scholar 

  26. West SD, Lee YC. Management of malignant pleural mesothelioma. Clin Chest Med. 2006;27:335–54. https://doi.org/10.1016/j.ccm.2006.01.004.

    Article  PubMed  Google Scholar 

  27. McAleer MF, Tsao AS, Liao ZX. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2009;75:326–37. https://doi.org/10.1016/j.ijrobp.2009.06.037.

    Article  PubMed  Google Scholar 

  28. Abdel-Rahman O. Role of postoperative radiotherapy in the management of malignant pleural mesothelioma. Strahlenther Onkol. 2017;193:276–84. https://doi.org/10.1007/s00066-016-1092-7.

    Article  PubMed  Google Scholar 

  29. Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother Oncol. 2006;80:13–8. https://doi.org/10.1016/j.radonc.2006.06.002.

    Article  PubMed  Google Scholar 

  30. Munter MW, Nill S, Thilmann C, Hof H, Hoss A, Haring P, et al. Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma – feasibility and initial results. Strahlenther Onkol. 2003;179:535–41. https://doi.org/10.1007/s00066-003-1055-7.

    Article  PubMed  Google Scholar 

  31. Rice DC, Smythe WR, Liao ZX, Guerrero T, Chang JY, McAleer MF, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007;69:350–7. https://doi.org/10.1016/j.ijrobp.2007.03.011.

    Article  PubMed  Google Scholar 

  32. Fuccio C, Spinapolice EG, Ferretti A, Castellucci P, Marzola MC, Trifiro G, et al. F-18-FDG-PET/CT in malignant mesothelioma. Biomed Pharmacother. 2013;67:539–42. https://doi.org/10.1016/j.biopha.2013.01.008.

    Article  CAS  PubMed  Google Scholar 

  33. Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res. 2010;16:2409–17. https://doi.org/10.1158/1078-0432.CCR-09-2313.

    Article  CAS  PubMed  Google Scholar 

  34. Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT. Eur J Radiol. 2012;81:E19–25. https://doi.org/10.1016/j.ejrad.2010.11.006.

    Article  PubMed  Google Scholar 

  35. Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer. 2010;67:311–7. https://doi.org/10.1016/j.lungcan.2009.04.015.

    Article  PubMed  Google Scholar 

  36. Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, et al. Volume-based parameter of F-18-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17:2787–94. https://doi.org/10.1245/s10434-010-1107-z.

    Article  PubMed  Google Scholar 

  37. Lee ST, Ghanem M, Herbertson RA, Berlangieri SU, Byrne AJ, Tabone K, et al. Prognostic value of F-18-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol. 2009;11:473–9. https://doi.org/10.1007/s11307-009-0203-6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maria Picchio.

Ethics declarations

Conflicts of interest

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Research Committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Incerti, E., Broggi, S., Fodor, A. et al. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. Eur J Nucl Med Mol Imaging 45, 2071–2078 (2018). https://doi.org/10.1007/s00259-018-4056-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-018-4056-6

Keywords

Navigation